Patents by Inventor Alla Pritsker

Alla Pritsker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240067740
    Abstract: The present disclosure provides antibodies and antibody fragments thereof that bind to human TNFR2. The disclosed antibodies, inhibit the TNF-TNFR2 signaling axis and enhance cytokine secretion in T effector cells and are therefore useful for the treatment of cancer, either alone or in combination with other agents.
    Type: Application
    Filed: December 30, 2021
    Publication date: February 29, 2024
    Inventors: Yi PEI, Haichun HUANG, Ming LEI, Han LI, Chi Shing SUM, Alla PRITSKER, Bor-Ruei LIN, Fangqiang TANG
  • Publication number: 20230399388
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: December 9, 2022
    Publication date: December 14, 2023
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20230295346
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Application
    Filed: March 9, 2023
    Publication date: September 21, 2023
    Inventors: Stanley R. Krystek, JR., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • Patent number: 11623965
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: April 11, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stanley R. Krystek, Jr., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • Publication number: 20230015181
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Application
    Filed: June 17, 2022
    Publication date: January 19, 2023
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Publication number: 20200115441
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: September 24, 2019
    Publication date: April 16, 2020
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20190359729
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAT-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAT-1 in the active conformational state.
    Type: Application
    Filed: August 6, 2019
    Publication date: November 28, 2019
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Patent number: 10465002
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: November 5, 2019
    Assignee: SANOFI
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20190055321
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 21, 2019
    Inventors: Stanley R. Krystek, JR., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • Publication number: 20180222967
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: December 18, 2017
    Publication date: August 9, 2018
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20180155444
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Application
    Filed: November 10, 2017
    Publication date: June 7, 2018
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Patent number: 9879079
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: January 30, 2018
    Assignee: SANOFI
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Patent number: 9845363
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: December 19, 2017
    Assignee: Sanofi
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Publication number: 20160368976
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kanidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kanidin activity or detect Kallidin or des-Arg10-Kanidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Application
    Filed: May 25, 2016
    Publication date: December 22, 2016
    Applicant: Sanofi
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
  • Publication number: 20160200831
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Application
    Filed: August 13, 2014
    Publication date: July 14, 2016
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirer, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Patent number: 9376494
    Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 28, 2016
    Assignee: Sanofi
    Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen